Capricor Therapeutics Inc (CAPR)

[mick]

Capricor Therapeutics (CAPR) BidaskScore is increased to Sold
2021-05-18
The BidaskScore of Capricor Therapeutics Inc Sold CAPR shows that the shares of the company are now sold by investors.

The BidaskScore of the Health Care shows that the sector is Strongly Bought Strongly Soldsince March 25.



Here are the BidaskScore of other related companies in the Biotechnology sector:
Aileron Therapeutics Inc Strongly Sold ALRN is Strongly Sold since April 13
Catalyst Biosciences Inc Strongly Sold CBIO is Strongly Sold since April 13
Synlogic Inc Held SYBX is Held since April 28
Galectin Therapeutics Inc Held GALT is Held since April 30
TRACON Pharmaceuticals Inc Sold TCON is Sold since May 6


Company description
Capricor Therapeutics, Inc. engages in the discovery, development and commercialization of first-in-class biological therapies for the treatment of cardiac and other serious medical conditions. Its product candidate consists of CAP-1002, Cenderitide, Exosomes, CAP-1001, CU-NP and CSps. The company was founded in August 2005 and is headquartered in Beverly Hills, CA.

https://capricor.com



’s adaptive algorithm uses the latest innovations in financial analysis and computing calculations to provide you with the BidaskScore.

Our algorithm processes daily a large set of US stock exchanges related data to determine investors’ capital allocation decision among single name equities and sectors.

The algorithm removes the short-term market’s noise that is embedded in every single stock’s price to keep only the long-term investors’ view on every single name equities and sectors.

We are convinced that the BidaskScore is the best scoring system currently available to let you see and understand investor’s positioning in every single name equities and sectors.